Literature DB >> 33573129

Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories.

Sofia O D Duarte1, Gabriel A Monteiro1,2.   

Abstract

The Lactococcus lactis bacterium found in different natural environments is traditionally associated with the fermented food industry. But recently, its applications have been spreading to the pharmaceutical industry, which has exploited its probiotic characteristics and is moving towards its use as cell factories for the production of added-value recombinant proteins and plasmid DNA (pDNA) for DNA vaccination, as a safer and industrially profitable alternative to the traditional Escherichia coli host. Additionally, due to its food-grade and generally recognized safe status, there have been an increasing number of studies about its use in live mucosal vaccination. In this review, we critically systematize the plasmid replicons available for the production of pharmaceutical-grade pDNA and recombinant proteins by L. lactis. A plasmid vector is an easily customized component when the goal is to engineer bacteria in order to produce a heterologous compound in industrially significant amounts, as an alternative to genomic DNA modifications. The additional burden to the cell depends on plasmid copy number and on the expression level, targeting location and type of protein expressed. For live mucosal vaccination applications, besides the presence of the necessary regulatory sequences, it is imperative that cells produce the antigen of interest in sufficient yields. The cell wall anchored antigens had shown more promising results in live mucosal vaccination studies, when compared with intracellular or secreted antigens. On the other side, engineering L. lactis to express membrane proteins, especially if they have a eukaryotic background, increases the overall cellular burden. The different alternative replicons for live mucosal vaccination, using L. lactis as the DNA vaccine carrier or the antigen producer, are critically reviewed, as a starting platform to choose or engineer the best vector for each application.

Entities:  

Keywords:  Lactococcus lactis; live mucosal vaccination; plasmid DNA; replicon

Year:  2021        PMID: 33573129      PMCID: PMC7866527          DOI: 10.3390/ijms22031379

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  181 in total

1.  Construction of plasmid vector for expression of bacteriocin N15-encoding gene and effect of engineered bacteria on Enterococcus faecalis.

Authors:  Monthon Lertcanawanichakul
Journal:  Curr Microbiol       Date:  2007-01-02       Impact factor: 2.188

2.  Lactococcus lactis carrying a DNA vaccine coding for the ESAT-6 antigen increases IL-17 cytokine secretion and boosts the BCG vaccine immune response.

Authors:  V B Pereira; V P da Cunha; T M Preisser; B M Souza; M Z Turk; C P De Castro; M S P Azevedo; A Miyoshi
Journal:  J Appl Microbiol       Date:  2017-05-03       Impact factor: 3.772

Review 3.  Vaccination strategies for mucosal immune responses.

Authors:  P L Ogra; H Faden; R C Welliver
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  Construction of Lactococcus lactis expressing secreted and anchored Eimeria tenella 3-1E protein and comparison of protective immunity against homologous challenge.

Authors:  Chunli Ma; Lili Zhang; Mingyang Gao; Dexing Ma
Journal:  Exp Parasitol       Date:  2017-05-17       Impact factor: 2.011

5.  The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403.

Authors:  A Bolotin; P Wincker; S Mauger; O Jaillon; K Malarme; J Weissenbach; S D Ehrlich; A Sorokin
Journal:  Genome Res       Date:  2001-05       Impact factor: 9.043

6.  Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.

Authors:  Ulrik H Mistarz; Susheel K Singh; Tam T T N Nguyen; Will Roeffen; Fen Yang; Casper Lissau; Søren M Madsen; Astrid Vrang; Régis W Tiendrebeogo; Ikhlaq H Kana; Robert W Sauerwein; Michael Theisen; Kasper D Rand
Journal:  Pharm Res       Date:  2017-06-23       Impact factor: 4.200

7.  Lactococcus lactis, an alternative system for functional expression of peripheral and intrinsic Arabidopsis membrane proteins.

Authors:  Annie Frelet-Barrand; Sylvain Boutigny; Lucas Moyet; Aurélien Deniaud; Daphné Seigneurin-Berny; Daniel Salvi; Florent Bernaudat; Pierre Richaud; Eva Pebay-Peyroula; Jacques Joyard; Norbert Rolland
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

8.  A food-grade engineered Lactococcus lactis strain delivering Helicobacter pylori Lpp20 alleviates bacterial infection in H. pylori-challenged mice.

Authors:  Nan Sun; Rongguang Zhang; Guangcai Duan; Xiaoyan Peng; Chen Wang; Shuaiyin Chen; Qingtang Fan
Journal:  Biotechnol Lett       Date:  2019-10-16       Impact factor: 2.461

9.  A new plasmid vector for DNA delivery using lactococci.

Authors:  Valeria Guimarães; Sylvia Innocentin; Jean-Marc Chatel; François Lefèvre; Philippe Langella; Vasco Azevedo; Anderson Miyoshi
Journal:  Genet Vaccines Ther       Date:  2009-02-10

10.  Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer's disease and Parkinson's disease.

Authors:  Xin Fang; Xiaoting Zhou; Yuqing Miao; Yiwen Han; Jing Wei; Tingtao Chen
Journal:  AMB Express       Date:  2020-04-24       Impact factor: 3.298

View more
  1 in total

Review 1.  Targeting Antigens for Universal Influenza Vaccine Development.

Authors:  Quyen-Thi Nguyen; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.